Pharmaceuticals

Oral Biologics & Biosimilars Market Outlook 2026–2030: Key Business Drivers and Trends

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oral biologics & biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Oral Biologics & Biosimilars Market in 2026, and what figure is it projected to hit by 2030?

The oral biologics & biosimilars market has seen substantial expansion in recent years. It is anticipated to increase from $9.37 billion in 2025 to $11.28 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.3%. Historically, this growth can be linked to the restricted availability of oral biologics, the high expense of biologic treatments, the common reliance on injectable formulations, the rising incidence of chronic diseases, and the development of hospital and retail pharmacy networks.

The oral biologics & biosimilars market size is anticipated to undergo substantial growth in the next few years. It is projected to reach $24.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.6%. The expansion during the forecast period can be attributed to the development of biosimilars and combination therapies, the broadening of oral biologics pipelines, an increasing patient inclination towards oral medications, the rising adoption of digital adherence tools, and growing government support and reimbursement policies. Significant trends in the forecast period include the increasing uptake of oral biologics and biosimilars for chronic diseases, a surge in targeted therapies for diabetes, arthritis, and cancer, the accelerated development of monoclonal antibody-based oral treatments, the widening of distribution channels through hospital, retail, and online pharmacies, and an emphasis on patient adherence and personalized treatment plans.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Drivers Are Affecting Market Participation In The Oral Biologics & Biosimilars Market?

The increasing incidence of chronic diseases is anticipated to drive the expansion of the oral biologics and biosimilar market. These enduring medical conditions, such as diabetes, cardiovascular diseases, and respiratory disorders, characteristically advance slowly. A key contributor to the rise in chronic diseases is sedentary lifestyles, as prolonged physical inactivity escalates the risk of obesity, heart disease, type 2 diabetes, and certain cancers. Oral biologics and biosimilars address this need by providing more accessible, cost-effective, and convenient treatment options for patients managing chronic conditions. For example, in January 2023, the Centers for Disease Control and Prevention (CDC), a US federal agency, reported that in 2023, 76.4% of U.S. adults (approximately 194 million people) had at least one chronic condition. Prevalence rates were noted at 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the growing prevalence of chronic diseases is a significant driver for the oral biologics and biosimilar market.

What Segment Classifications Make Up The Oral Biologics & Biosimilars Market?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Which Competitive Trends Are Impacting The Structure Of The Oral Biologics & Biosimilars Market?

Leading entities within the oral biologics & biosimilars market are dedicating efforts to devising cutting-edge solutions, including specialized smart capsule development services, aimed at advancing the oral administration of biologics, boosting their bioavailability, and facilitating more patient-friendly usage than conventional injectable formats. These smart capsules incorporate sophisticated coatings, regulated-release matrices, or protective excipients, which shield biologics from breakdown in the gastrointestinal tract and enhance absorption in specific intestinal areas, thereby providing a non-invasive option to injections and boosting patient compliance. A notable example is Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), which introduced a customized service for smart capsule development in December 2024, specifically aiding oral biologics development. This service incorporates bespoke formulation design, selection of protective excipients, and advanced capsule engineering to guarantee the stability and precise release of biologics; its mechanism involves improving the oral bioavailability of delicate biomolecules while preserving their therapeutic effectiveness. Its distinctive attributes comprise comprehensive support from initial concept through preclinical testing, adaptability with diverse biologic modalities such as proteins, peptides, and nucleic acids, and readily scalable manufacturing options. The applications cover the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines; the advantages encompass greater patient comfort, diminished dependence on injections, better adherence, and faster development cycles for oral biologic treatments.

Which Major Industry Participants Are Leading The Oral Biologics & Biosimilars Market Growth?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Biologics & Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795